Santhera Pharmaceuticals

Showing 2 posts of 2 posts found.

NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera

January 29, 2025
Sales and Marketing Duchenne Muscular Dystrophy, EC, EMA, FDA, Santhera Pharmaceuticals, positive

Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence (NICE) for AGAMREE (vamorolone) to …

Santhera Pharmaceuticals announces LIONHEART study results for corticosteroid vamorolone

October 1, 2024
Research and Development Cardiology, Duchenne Muscular Dystrophy, Immunology, Santhera Pharmaceuticals, clinical studies

Santhera Pharma has announced the results of its LIONHEART study, which evaluated vamorolone – a corticosteroid – and confirmed its …

The Gateway to Local Adoption Series

Latest content